Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Emerito Carlos Rodriguez-Merchan Disclosures Expert Rev Hematol. 2013;6 (6):637-642.

World First Artificial Solar Eclipse Created, The “Closest Thing” To HIV Vaccine Gets FDA Approval, And Much More This Week All the biggest science news stories of the week. Charlie Haigh ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...

Acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) pilot will give the company more opportunities to interact with regulatory authorities. It comes after the company’s Gradient ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa ...